Dr. Francesca Duncan and her colleagues recently published in the Proceedings of the National Academy of Sciences (PNAS).
This paper "mTORC1/2 Inhibition Preserves Ovarian Function and Fertility during Genotoxic Chemotherapy" is significant for the following reasons: "A major unresolved issue for premenopausal women undergoing chemotherapy is infertility due to the loss of nonrenewable ovarian primordial follicles. We show that pharmacologic down-regulation of the mammalian/mechanistic target of rapamycin (mTOR) pathway during chemotherapy in a mouse model prevents activation of primordial follicles, preserves ovarian function, and maintains normal fertility using clinically available inhibitors of mTOR complex (C)1 and mTORC1/2. These findings represent a feasible pharmacologic approach for preservation of ovarian function and fertility during treatment with conventional chemotherapy."
The contents of the Oncofertility Consortium Blog are for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
965 Wilson Road, Room A626B
East Lansing, MI 48824-1316
Phone: 1 (517) 884 6434
Ownership of this website has been transferred from Northwestern University to Michigan State University. Please note that some site information may be inaccurate while adjustments to reflect this organizational change are made.